Actinium Pharmaceuticals
ATNM
24 hedge funds and large institutions have $8.12M invested in Actinium Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 8 closing their positions.
87% more capital invested
Capital invested by funds: $4.33M → $8.12M (+$3.79M)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% less ownership
Funds ownership: 0.2% → 0.2% (-0%)
11% less funds holding
Funds holding: 27 → 24 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
72% less call options, than puts
Call options by funds: $62K | Put options by funds: $221K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$402K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$275K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$241K |
| 4 |
Bank of New York Mellon
New York
|
+$157K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$292K |
| 2 |
Goldman Sachs
New York
|
-$169K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$159K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$121K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Goldman Sachs
New York
| – | -$169K | -3,178 | Closed |
|
|
DCM
27
DAFNA Capital Management
Los Angeles,
California
| – | -$159K | -3,000 | Closed |
|
|
SM
28
Sabby Management
Miami Beach,
Florida
| – | -$121K | -2,281 | Closed |
|
|
VKH
29
Virtu KCG Holdings
New York
| – | -$93K | -1,759 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$13K | -247 | Closed |
|
31
Simplex Trading
Chicago,
Illinois
| – | -$13.3K | -200 | Closed |
|
|
BJ
32
BlackRock Japan
Tokyo,
Japan
| – | -$4K | -75 | Closed |
|
ATNM Hedge Fund Activity: Q4 2015 in Review
24 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2015, worth a combined $8.12M — up 87% from $4.33M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ATNM and 5 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $402K. The largest seller was Millennium Management, exiting entirely with an estimated $292K sold.
- 24 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2015, down from 27 in Q3 2015.
- Funds reported $8.12M of Actinium Pharmaceuticals stock for Q4 2015, up 87% quarter-over-quarter.
- 5 funds opened new Actinium Pharmaceuticals positions in Q4 2015 and 8 closed out, a net change of -3 holders.
- The largest Actinium Pharmaceuticals buyer in Q4 2015 was Vanguard Group, an estimated $402K added.
- The largest Actinium Pharmaceuticals seller in Q4 2015 was Millennium Management, an estimated $292K sold.
Based on aggregated 13F filings for Q4 2015.